相关实验视频
Updated: Jun 12, 2025

09:10
Synthesis of Indoxyl-glycosides for Detection of Glycosidase Activities
Published on: May 27, 2015
6.6K
作为人类保留β-葡萄糖酶抑制剂的脱氧cyclophellitols的合成和生物评估
Yevhenii Radchenko1, Qin Su1, Sybrin S Schröder1
1Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands.
Chemistry (Weinheim an der Bergstrasse, Germany)
|September 21, 2024
概括
研究人员开发了新型环利醇亚齐里丁,作为人类保留β-葡萄糖酶的基于活动的探针. 这些探针可以对GBA3或GBA1/GBA2进行选择性检测,有助于对β-葡萄糖酶功能的研究.
科学领域:
- 生物化学 生物化学
- 化学生物学 化学生物学
- 酶学 是一种酶学.
背景情况:
- 环利醇是一种已知的保留β-葡萄糖酶的抑制剂.
- 基于活动的探针 (ABP) 是研究酶功能的关键工具.
- 人类保留β-葡萄糖酶 (GBA1,GBA2,GBA3) 在细胞过程中起着重要的作用.
研究的目的:
- 合成新型环利醇衍生物和环利醇亚齐里丁作为潜在的ABP.
- 评估这些化合物对人类GBA1,GBA2和GBA3.3的抑制功效和选择性.
- 开发选择性探针,以区分这三种β-葡萄糖酶.
主要方法:
- 合成八个单和二氧化环利托和环利托亚齐里丁的合成.
- 开发以亚齐里丁为基础的ABP,使用生物或光剂功能化.
- 酶抑制试验以确定对GBA1,GBA2和GBA3.3的功效.
- 使用过度表达的GBA2和GBA3进行细胞测试,以评估探头的选择性.
主要成果:
- 成功合成了24种新型环利醇衍生物和亚齐里丁.
- 证明了对GBA1,GBA2和GBA3的不同抑制功效.
- 确定了一种特定的3,6-二氧化碳-β-银环利醇亚齐里丁探针,可以选择性地捕获GBA3.
- 发现了另一种探针,可以在较低度下选择性地标记GBA1和GBA2,而不是GBA3.
结论:
- 建立了性环醇环氧化物和亚齐里丁的新合成途径.
- 现在可以使用一个扩展的循环利托尔基化合物库,具有多样化的替代模式.
- 开发的探针为研究人类保留β-葡萄糖酶的独特生理作用和治疗相关性提供了有价值的工具,特别是难以捉摸的GBA3.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Glucagon-like Receptor Agonists
305
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
305

